2012

London, UK, 12 June 2012 BTG plc (LSE: BTG), the specialist healthcare company, notes today’s announcement by Sanofi and its subsidiary Genzyme, relating to the submission of a supplemental...

West Conshohocken, PA, 04 June 2012 BTG International Inc., the specialist healthcare company, today announces the presentation of data on Voraxaze®(glucarpidase) at the American Society of...

London, UK, 25 May 2012 BTG plc (LSE: BGC), the specialist healthcare company, today announces that Louise Makin, CEO, will be presenting at the Jefferies Global Healthcare Conference in New York,...

London, UK, 21 May 2012 BTG plc (LSE: BGC), the specialist healthcare company, today announces its final results for the year ended 31 March 2012. Click here to download the PDF

West Conshohocken, PA, 30 April 2012 BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze® (glucarpidase) in the US. Voraxaze® is indicated for the...

London, UK, 23 April 2012 BTG plc (LSE: BGC), the specialist healthcare company, today announces the successful outcome of VANISH-1, the second and final US pivotal Phase III trial of Varisolve®...

London, UK, 04 April 2012 BTG plc (LSE: BGC), the specialist healthcare company, provides the following update for the year ended 31 March 2012 ahead of the planned publication of its Final...

London, UK, 28 March 2012 Powder for solution for infusion Launched in the UK, BTG, the specialist healthcare company today announces the launch of DigiFab® in the UK through Protherics Medicines...

London, UK, 08 March 2012 Regulatory applications to be submitted in the US and around the world beginning in H2 2012 seeking approval for use in men with CRPC who have not yet received...

London, UK, 20 February 2012 BTG plc (LSE: BGC), the specialist healthcare company today announces that it will be presenting at the Citi Global Health Care Conference in New York, US on Tuesday,...

Show 5102550100 per page
Top